Kexing Biopharm Co., Ltd. (688136.SH) Latest Company News

Oct 29, 2026, 08:40 UTC
Kexing Biopharm reported 2026 first-three-quarter revenue of RMB 914 million, down 20.38% year over year, net profit attributable to shareholders of RMB 26.058 million, down 76.58%, and adjusted net loss of RMB 166 million; third-quarter revenue was RMB 307 million, down 31.43%, and net loss attributable to shareholders was RMB 108 million.
Source:
- finance.sina.cn
Oct 20, 2026, 02:10 UTC
Pakistan’s Drug Regulatory Authority granted marketing authorization for Shandong Boan Biotechnology Co., Ltd.’s aflibercept intravitreal injection solution, which was introduced by Kexing Biopharm.
Source:
- finance.sina.cn
Oct 9, 2026, 11:00 UTC
China's National Medical Products Administration accepted Shenzhen Xinguang Pharmaceutical's marketing authorization application for its investigational pegylated human granulocyte colony-stimulating factor injection GB-K02.
Source:
- finance.sina.cn
Sep 21, 2026, 08:01 UTC
Kexing Biopharm's wholly owned subsidiary Shenzhen Kexing Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials of GB20 injection for inflammatory bowel disease, including ulcerative colitis and Crohn's disease.
Source:
- finance.sina.cn
Aug 27, 2026, 03:44 UTC
Kexing Pharmaceutical signed a commercialization cooperation agreement with Huayi Taikang Pharmaceutical to jointly promote the commercialization of metoprolol succinate extended-release tablets in the Hong Kong, China market, with Kexing responsible for registration and commercialization.
Source:
- finance.sina.cn
Aug 21, 2026, 10:05 UTC
Kexing Pharmaceutical announced its first-half 2026 results: revenue of 607 million yuan, net profit of 134 million yuan, up 66.71% year-on-year.
Source:
- finance.sina.cn
Jun 24, 2026, 03:54 UTC
Kexing Biopharm received the R&D Innovation Award at the CPHI Award ceremony.
Source:
- finanznachrichten.de
- boerse.de
Jun 24, 2026, 03:54 UTC
Kexing Biopharm showcased multiple self-developed innovative drug pipelines and over 30 products at the CPHI & PMEC China 2026 exhibition.
Source:
- finanznachrichten.de
- boerse.de

688136.SH

Pakistan’s Drug Regulatory Authority granted marketing authorization for Shandong Boan Biotechnology Co., Ltd.’s aflibercept intravitreal injection solution, which was introduced by Kexing Biopharm.

China's National Medical Products Administration accepted Shenzhen Xinguang Pharmaceutical's marketing authorization application for its investigational pegylated human granulocyte colony-stimulating factor injection GB-K02.

Kexing Biopharm's wholly owned subsidiary Shenzhen Kexing Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials of GB20 injection for inflammatory bowel disease, including ulcerative colitis and Crohn's disease.

Kexing Pharmaceutical signed a commercialization cooperation agreement with Huayi Taikang Pharmaceutical to jointly promote the commercialization of metoprolol succinate extended-release tablets in the Hong Kong, China market, with Kexing responsible for registration and commercialization.

Kexing Pharmaceutical announced its first-half 2026 results: revenue of 607 million yuan, net profit of 134 million yuan, up 66.71% year-on-year.

Kexing Biopharm received the R&D Innovation Award at the CPHI Award ceremony.

Kexing Biopharm showcased multiple self-developed innovative drug pipelines and over 30 products at the CPHI & PMEC China 2026 exhibition.